PRA Health Sciences, Inc. (PRAH) Scheduled to Post Earnings on Tuesday
PRA Health Sciences, Inc. (NASDAQ:PRAH) will be posting its quarterly earnings results after the market closes on Tuesday, October 31st. Analysts expect PRA Health Sciences to post earnings of $0.85 per share for the quarter. PRA Health Sciences has set its FY17 guidance at $3.11-$3.20 EPS.
PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.10). PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The business had revenue of $457.90 million for the quarter, compared to analysts’ expectations of $447.79 million. During the same period last year, the firm posted $0.63 earnings per share. PRA Health Sciences’s quarterly revenue was up .5% on a year-over-year basis. On average, analysts expect PRA Health Sciences to post $3.08 EPS for the current fiscal year and $3.77 EPS for the next fiscal year.
PRA Health Sciences, Inc. (NASDAQ PRAH) traded up 0.29% during trading on Tuesday, hitting $81.80. The stock had a trading volume of 44,674 shares. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of 52.81 and a beta of 0.42. PRA Health Sciences, Inc. has a 12 month low of $50.87 and a 12 month high of $83.73. The stock has a 50 day moving average price of $78.09 and a 200-day moving average price of $73.66.
PRAH has been the topic of several research reports. Bank of America Corporation initiated coverage on PRA Health Sciences in a report on Monday, June 26th. They set a “buy” rating and a $89.00 price objective on the stock. Citigroup Inc. restated a “buy” rating and set a $90.00 price objective (up from $73.00) on shares of PRA Health Sciences in a report on Wednesday, June 28th. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Robert W. Baird raised their price objective on PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. Finally, Credit Suisse Group raised their price objective on PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. PRA Health Sciences presently has a consensus rating of “Buy” and a consensus target price of $85.44.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/24/pra-health-sciences-inc-prah-scheduled-to-post-earnings-on-tuesday.html.
In other news, CEO Colin Shannon sold 400,000 shares of PRA Health Sciences stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of PRA Health Sciences stock in a transaction on Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $711,075,000.00. The disclosure for this sale can be found here. Insiders sold a total of 10,000,000 shares of company stock worth $748,500,000 over the last quarter. Company insiders own 2.10% of the company’s stock.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.